GXI has been the subject of a number of other research reports. Commerzbank set a €68.00 ($79.07) price target on Gerresheimer and gave the company a neutral rating in a research note on Wednesday, August 29th. Hauck & Aufhaeuser set a €52.50 ($61.05) target price on Gerresheimer and gave the stock a sell rating in a research note on Monday, July 16th. Berenberg Bank set a €85.00 ($98.84) target price on Gerresheimer and gave the stock a buy rating in a research note on Friday, July 27th. Goldman Sachs Group set a €70.00 ($81.40) target price on Gerresheimer and gave the stock a neutral rating in a research note on Monday, June 18th. Finally, HSBC set a €67.00 ($77.91) target price on Gerresheimer and gave the stock a neutral rating in a research note on Monday, July 16th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Gerresheimer presently has a consensus rating of Hold and a consensus price target of €71.67 ($83.33).
GXI stock traded down €2.85 ($3.31) during midday trading on Friday, reaching €61.50 ($71.51). The company had a trading volume of 389,276 shares, compared to its average volume of 140,925. Gerresheimer has a 1-year low of €59.97 ($69.73) and a 1-year high of €78.25 ($90.99).
Gerresheimer Company Profile
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
See Also: Stock Symbols and CUSIP Explained
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.